Vaccination of 27- to 45-year-olds against HPV is less cost-effective than vaccination of younger persons (aged 9 to 26 years).

COVID-19, influenza, and RSV vaccination coverage is low among nursing home residents early in the 2024 to 2025 season.

Baricitinib is an effective treatment option for children and adolescents with atopic dermatitis, with no new safety signals identified.

Tumor characteristics differ significantly among pediatric and adolescent and young AYA patients with melanoma, with decreasing incidence rates seen among young patients with cutaneous melanoma.

Poor control over specific aspects of work is associated with burnout among physicians, according to study findings.

Preterm infants have thicker superficial components and more stepped borders for infantile hemangioma when compared with term infants.

Deucravacitinib outperformed placebo for treating moderate to severe scalp psoriasis, even among patients with less extensive overall disease.

No new safety concerns were observed through 16 weeks among pediatric patients with juvenile psoriatic arthritis or enthesitis-related arthritis receiving ixekizumab. Ixekizumab (IXE) demonstrated ...

Risankizumab had greater improvements in skin clearance and quality of life at 16 weeks in patients with psoriasis compared with deucravacitinib.

Topline results were announced from a phase 3 trial evaluating icotrokinra in patients with moderate to severe plaque psoriasis (PsO).

Seasonal maternal respiratory syncytial virus vaccination and nirsevimab for infants demonstrate cost-effectiveness.

Based on the current trajectory, overweight and obesity will continue increasing in the United States up to 2050.